Contrarian watchlist stock updates

Which stocks just entered the contrarian watchlist?

{"response_type": "market_analysis", "acknowledgement": "Here's a list of stocks with notably low Z-scores entering the contrarian watchlist.", "answer": "The following stocks are currently flagged with very low Z-scores, indicating contrarian valuation opportunities:\n- **PLTR (PALANTIR TECHNOLOGIES INC)**, Technology, Mega Cap\n- **CPRT (COPART INC)**, Industrials, Large Cap\n- **FNV (FRANCO NEVADA CORP)**, Basic Materials, Large Cap\n- **UTHR (UNITED THERAPEUTICS CORP)**, Healthcare, Large Cap\n- **ENLV (ENLIVEX LTD)**, Healthcare, Micro Cap\n- **RDDT (REDDIT INC)**, Communication Services, Large Cap\n- **MLI (MUELLER INDUSTRIES INC)**, Industrials, Large Cap\n\nThese stocks are displaying low Z-scores, which often suggest undervaluation relative to their fundamentals or market sentiment but may also indicate potential risks. They could be interesting candidates for contrarian strategies, especially if negative sentiment is driven by temporary or non-fundamental factors. The data reflects their status at last available session.", "interpretation": "The low Z-scores suggest these stocks may be undervalued or out of favor, presenting contrarian opportunities. However, some, like ENLV with a high upside forecast, could also carry risks or unique circumstances requiring further analysis. These stocks should be assessed carefully for turnaround potential versus structural issues.", "hypothesis": {"text": "The low Z-scores are driven by market overreactions or temporary sentiment dips, not fundamental deterioration.", "confidence": "Moderate"}, "insights": ["Most stocks are from diverse sectors, indicating broad contrarian potential.", "Several stocks, like ENLV, show high upside potential despite low Z-scores."], "suggested_questions": ["Check the recent earnings of PLTR", "Compare CPRT with sector peers", "Search latest news on ENLV"], "charts": [], "actions": [], "supporting_data": [{"label": "Rank: PLTR", "value": "zscore=9.0", "source": "metrics"}, {"label": "Rank: CPRT", "value": "zscore=9.0", "source": "metrics"}, {"label": "Rank: FNV", "value": "zscore=9.0", "source": "metrics"}, {"label": "Rank: UTHR", "value": "zscore=9.0", "source": "metrics"}, {"label": "Rank: ENLV", "value": "zscore=9.0", "source": "metrics"}], "risk_watch": "", "structured_data": null}

Search latest news on ENLV

{"response_type": "market_analysis", "acknowledgement": "Here's the latest news on ENLV from the past week.", "answer": "- **HC Wainwright & Co. Maintains Buy on Enlivex, Raises Price Target to $80** *(Benzinga, Aug 3 06:30)*: Analyst Raghuram Selvaraju sustained a Buy rating on ENLV and increased the price target from $20 to $80.", "interpretation": "This positive analyst update reflects improved sentiment toward ENLV, highlighting potential for significant price appreciation despite recent weakness. Investors might want to investigate the catalyst behind the higher target, such as clinical progress or commercial developments, given ENLV's micro-cap status and large recent drawdown.", "hypothesis": {"text": "The boosted price target by HC Wainwright may signal upcoming positive developments or improved financial outlook for ENLV.", "confidence": "Moderate"}, "insights": ["ENLV's price target from HC Wainwright surged +300%, signaling strong bullish outlook.", "Only one major recent analyst action detected, suggesting limited current research coverage."], "suggested_questions": ["Review ENLV financials and valuation metrics", "Check recent ENLV earnings history", "Compare ENLV with healthcare micro-cap peers"], "charts": [], "actions": [{"label": "Analyze ENLV financials", "action_type": "analyze_stock", "parameters": {"ticker": "ENLV"}}, {"label": "Check ENLV earnings history", "action_type": "earnings_transcript_search", "parameters": {"ticker": "ENLV"}}], "supporting_data": [], "risk_watch": "", "structured_data": null}

Compare ENLV with healthcare micro-cap peers

{"response_type": "market_analysis", "acknowledgement": "Comparing ENLV with its healthcare micro-cap peers in biotechnology.", "answer": "- ENLV (Enlivex Ltd.) is a micro-cap healthcare stock with a market cap around $33 million.\n- Key valuation metrics show ENLV with an extremely low trailing P/E of approximately 0.0054, a negative forward P/E of about -2.67, and a very low price-to-book ratio near 0.017, reflecting very depressed valuation levels.\n- ENLV has reported significant net income of approximately $1.24 billion, which seems unusual given its size and might warrant further verification or context.\n- ENLV's EV/EBITDA is negative (-1.9), indicating negative operating earnings excluding certain costs.\n\n- Peers in the biotech industry such as United Therapeutics (UTHR), Vertex Pharmaceuticals (VRTX), and Regeneron (REGN) are large caps with AAA or AA credit ratings and more normalized valuation profiles.\n- ENLV stands out as a tiny micro-cap with extreme valuation contrasts, highlighting the risk and opportunity in such a stock versus established large-cap peers.", "interpretation": "ENLV\u2019s valuation and size profile are markedly different from its large-cap biotech peers, suggesting it carries very high risk and volatility but may also have potential for outsized returns if its fundamentals or clinical developments improve. The reported net income figure appears unusual for a company of its size and warrants further review to clarify financial health. Investors should consider the early-stage nature of ENLV alongside the stable revenue and credit quality of larger, established biotech firms.", "hypothesis": {"text": "ENLV\u2019s extreme valuation metrics likely reflect market skepticism about its fundamentals or growth prospects relative to large, well-established biotech peers.", "confidence": "Moderate"}, "insights": ["ENLV\u2019s market cap of approximately $33 million is drastically smaller than typical biotech peers, categorizing it as a micro-cap compared to large caps.", "The extremely low P/E and PB ratios imply a significant market discount or possible data anomalies that need further validation."], "suggested_questions": ["Investigate ENLV\u2019s recent financial reports", "Compare ENLV\u2019s credit rating with peers", "Analyze clinical trial progress for ENLV", "View ENLV page for more analysis"], "charts": [{"type": "bar", "title": "Market Cap (USD Billions) Comparison: ENLV vs Biotech Peers", "data": [{"label": "ENLV", "value": 0.035}, {"label": "UTHR", "value": 132.02}, {"label": "VRTX", "value": 125.73}, {"label": "REGN", "value": 80.75}, {"label": "NVO", "value": 209.55}, {"label": "ARGX", "value": 54.1}]}], "actions": [{"label": "Analyze ENLV financials", "action_type": "analyze_stock", "parameters": {"ticker": "ENLV"}}], "supporting_data": [], "risk_watch": "Visit the ENLV ticker page for full credit ratings, financial scores, and fundamental analysis.", "structured_data": {"template": "stock_comparison", "stocks": {"ENLV": {"name": "Enlivex Ltd.", "sector": "Healthcare", "market_cap": 35010592, "revenue": null, "net_income": 1235527936, "pe_trailing": 0.0054421765, "pe_forward": -2.6666667, "pb_ratio": 0.01701181, "ps_ratio": null, "ev_to_ebitda": -1.895, "dividend_yield": null, "beta": 1.465}}, "returns": {}}}